Control | Protocol | p Value | |
Total | 37 | 37 | |
% male | 67.6 | 67.6 | |
Age (years), mean (SD) | 52.6 (17.7) | 45.1 (13.8) | 0.07 |
APACHE II, mean (SD) | 24.9 (6.8) | 22.6 (8.1) | 0.26 |
Site of infection | |||
Lung | 21 | 26 | 0.23 |
Abdomen | 3 | 2 | 0.65 |
Endocarditis | 3 | 4 | 0.69 |
Skin | 4 | 5 | 0.72 |
Urinary tract | 1 | 4 | 0.17 |
CNS | 2 | 0 | 0.16 |
Line | 0 | 1 | 0.32 |
No site | 5 | 6 | 0.75 |
Comorbidities | |||
HIV | 17 | 14 | 0.48 |
Hepatitis B/hepatitis C | 24 | 16 | 0.06 |
Chronic renal failure | 4 | 3 | 0.69 |
Chronic liver failure | 3 | 2 | 0.65 |
CHF | 4 | 3 | 0.69 |
DM | 7 | 5 | 0.53 |
COPD | 3 | 4 | 0.69 |
Transplant | 1 | 1 | 1.00 |
APACHE II, Acute Physiology and Chronic Health Evaluation II; CNS, central nervous system; DM, diabetes mellitus.